These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 2058604)
21. Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children. Käyhty H; Peltola H; Eskola J Pediatr Infect Dis J; 1988 Aug; 7(8):574-7. PubMed ID: 3050853 [TBL] [Abstract][Full Text] [Related]
22. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067 [TBL] [Abstract][Full Text] [Related]
23. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. Weinberg GA; Einhorn MS; Lenoir AA; Granoff PD; Granoff DM J Pediatr; 1987 Jul; 111(1):22-7. PubMed ID: 3110388 [TBL] [Abstract][Full Text] [Related]
24. Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: evidence of decreased immunogenicity. Adderson EE; Chisholm N; Halperin SA Clin Invest Med; 1991 Aug; 14(4):338-45. PubMed ID: 1782732 [TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants. Hendley JO; Wenzel JG; Ashe KM; Samuelson JS Pediatrics; 1987 Sep; 80(3):351-4. PubMed ID: 3306597 [TBL] [Abstract][Full Text] [Related]
26. Age-dependent V region expression in the human antibody response to the Haemophilus influenzae type b polysaccharide. Lucas AH; Azmi FH; Mink CM; Granoff DM J Immunol; 1993 Mar; 150(5):2056-61. PubMed ID: 8436834 [TBL] [Abstract][Full Text] [Related]
27. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. Granoff DM; Anderson EL; Osterholm MT; Holmes SJ; McHugh JE; Belshe RB; Medley F; Murphy TV J Pediatr; 1992 Aug; 121(2):187-94. PubMed ID: 1640282 [TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and reactogenicity of Haemophilus influenzae type b-meningococcus group B outer membrane protein conjugate vaccine in children 2-60 months of age. Shehab ZM; Azimi P; Asmar BI; Dunphy MG; Ayoub EM; Dajani AS Scand J Infect Dis; 1991; 23(6):763-9. PubMed ID: 1815340 [TBL] [Abstract][Full Text] [Related]
29. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. Schlesinger Y; Granoff DM JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children. Lehmann D; Kakazo M; Saleu G; Taime J; Javati A; Namuigi P; Alpers MP; Wegmüller B; Zellmeyer M; Fürer E; Que JU; Herzog C P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673 [TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age. Käyhty H; Peltola H; Eskola J; Rönnberg PR; Kela E; Karanko V; Mäkelä PH Pediatrics; 1989 Dec; 84(6):995-9. PubMed ID: 2587155 [TBL] [Abstract][Full Text] [Related]
32. Studies on the combined administration of Haemophilus influenzae type B--diphtheria toxoid conjugate vaccine (PRP-D) and DTP. Gordon LK Dev Biol Stand; 1986; 65():113-21. PubMed ID: 3549393 [TBL] [Abstract][Full Text] [Related]
33. The immunogenicity of Hemophilus influenzae type B polysaccharide-Neisseria meningitidis group B outer membrane protein complex vaccine in infants and young children. Shapiro ED; Capobianco LA; Berg AT; Zitt MQ J Infect Dis; 1989 Dec; 160(6):1064-7. PubMed ID: 2511254 [TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population. Santosham M; Hill J; Wolff M; Reid R; Lukacs L; Ahonkhai V Pediatr Infect Dis J; 1991 Feb; 10(2):113-7. PubMed ID: 2062601 [TBL] [Abstract][Full Text] [Related]
35. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen. Bewley KM; Schwab JG; Ballanco GA; Daum RS Pediatrics; 1996 Nov; 98(5):898-904. PubMed ID: 8909483 [TBL] [Abstract][Full Text] [Related]
36. IgG subclass response to immunization with Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine. Granoff DM; Weinberg GA; Shackelford PG Pediatr Res; 1988 Aug; 24(2):180-5. PubMed ID: 3263612 [TBL] [Abstract][Full Text] [Related]
37. [Tolerance and immunogenicity of the capsular polyoside vaccine against Haemophilus influenzae type b. A study of 325 children 15 to 71 months of age]. Reinert P; Postel-Vinay A; Bessa E; Hessel L; Schulz D; Cadoz M Ann Pediatr (Paris); 1989 Jan; 36(1):20-5. PubMed ID: 2784652 [TBL] [Abstract][Full Text] [Related]
38. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197. Anderson PW; Pichichero ME; Stein EC; Porcelli S; Betts RF; Connuck DM; Korones D; Insel RA; Zahradnik JM; Eby R J Immunol; 1989 Apr; 142(7):2464-8. PubMed ID: 2784464 [TBL] [Abstract][Full Text] [Related]
39. Haemophilus influenzae type b immunization of children with sickle cell diseases. Frank AL; Labotka RJ; Rao S; Frisone LR; McVerry PH; Samuelson JS; Maurer H; Yogev R Pediatrics; 1988 Oct; 82(4):571-5. PubMed ID: 3262857 [TBL] [Abstract][Full Text] [Related]
40. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]